Merck unveils phase 3 data as Merck & Co. stock gains 1.70 percent

Published on 10/15/2026 at 10:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Merck's October 26 event covers oncology. Merck & Co. stock costs EUR 133.41 on October 15, 1.70 percent above the EUR 131.18 Xetra close.

Pipeline and governance updates

Merck presented first-time pivotal oncology trial results on October 13, 2026.
Second-quarter 2026 revenue reached USD 16.6 billion.
Merck & Co. stock trades at EUR 133.41 at 10:04 a.m. CEST at Lang & Schwarz on October 15, 2026, 1.70 percent above the Xetra close of October 14, 2026.

Bold pop art comic book illustration of a large stylized medical syringe in cyan, yellow, and red with thick black outlines, tilted diagonally at center. Radiating black speed lines burst outward from the syringe. Ben-Day halftone dot pattern in magenta a — Merck US58933Y1055 Pop-Art-Comic: Knallbunte stilisierte Spritze mit Halftone-Punkten, Farbblöcken und dynamischen Speed-Lines, Illustration mit AI erstellt.

Merck & Co. (ISIN US58933Y1055) presented first-time pivotal oncology trial results at the ESMO 2026 Congress, while its stock traded at EUR 133.41 at Lang & Schwarz on October 15, 2026, 1.70 percent above the Xetra close of October 14, 2026 at EUR 131.18. The company also scheduled an oncology investor event for October 26, 2026.

Pipeline data sharpen the focus

According to Merck & Co. on October 13, 2026, three pivotal clinical trial results were due for presentation at the European Society for Medical Oncology Congress in Madrid from October 23 to October 27. Management will discuss the oncology strategy during the October 26 investor event.

The financial base is substantial but uneven. Merck reported USD 16.607 billion in revenue for the second quarter of 2026, alongside a net loss attributable to common shareholders of USD 1.335 billion and diluted earnings per share of minus USD 0.54, according to the company's investor-relations materials.

What do the next dates mean?

The immediate calendar gives investors two separate reference points. The October 26 oncology event addresses pipeline development, while Merck & Co. scheduled its third-quarter sales and earnings call for October 29, 2026 at 9:00 a.m. ET.

Three recent company milestones

On October 10, 2026, Merck presented one-year results from the BRUNELLO study at the American Academy of Ophthalmology meeting. On October 13, 2026, StockTitan reported that Paul J. Diaz would join the board effective November 1, expanding it to 14 members. The same October 13 date brought the oncology pipeline update, making clinical execution the latest company-specific catalyst.

Stock stays above the Xetra close

Merck & Co. stock was trading at EUR 133.41 at Lang & Schwarz on October 15, 2026 at 10:04 a.m. CEST, 1.70 percent above the Xetra close of October 14, 2026 at EUR 131.18. The quote remains below the EUR 134.98 52-week high shown for the Xetra listing on October 15, 2026. The further course of trading is shown by the continuously updated real-time quote of Merck & Co. stock.